Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | TPO | P07202 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18077509 | 0.79 | GPR84 (0.42) | ARGPR84ELANEMEN1KMT2A | |
| SCHEMBL84651 | 0.71 | — | — | |
| SCHEMBL17700357 | 0.66 | JAK2 (0.46) | JAK2JAK1MEN1KMT2A | |
| SCHEMBL571512 | 0.63 | DAO (0.40) | GPR84KMT2A | |
| SCHEMBL28471255 | 0.62 | NPC1 (0.39) | JAK2JAK1ROCK2MEN1KMT2A | |
| SCHEMBL25533401 | 0.62 | HRH3 (0.38) | NUDT1MEN1KMT2A | |
| SCHEMBL16487279 | 0.61 | AR (0.38) | ARNUDT1MEN1KMT2A | |
| SCHEMBL2632908 | 0.61 | — | — | |
| SCHEMBL23943143 | 0.60 | NUDT1 (0.35) | NUDT1 | |
| SCHEMBL3749300 | 0.60 | AR (0.39) | JAK2JAK1ARNUDT1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947237-B2 | Antimicrobial compounds and methods of making and using the same | BioVersys AG (CH) | 2021-03-16 | — | — | US | disclosed |
| US-20180065966-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | MELINTA THERAPEUTICS, INC. | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065966-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | LPO, MPO, CAT | JAK2 3632/4885JAK1 3114/4885AR 4680/4885 |
| US-10947237-B2 | Antimicrobial compounds and methods of making and using the same | LPO, MPO, CAT | JAK2 3632/4885JAK1 3114/4885AR 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.